{
    "clinical_study": {
        "@rank": "114365", 
        "arm_group": {
            "arm_group_label": "lurbinectedin (PM01183) / cisplatin", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive cisplatin as a 90-min i.v. infusion. In addition, patients will receive PM01183 as an i.v. infusion over 1-hour."
        }, 
        "brief_summary": {
            "textblock": "Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Cisplatin\n      in Patients with Advanced Solid Tumors to determine the recommended dose (RD) of PM01183 in\n      combination with cisplatin, to characterize the safety profile, the pharmacokinetics (PK) of\n      this combination, to obtain preliminary information on the clinical antitumor activity and\n      to conduct an exploratory pharmacogenomic (PGx) analysis."
        }, 
        "brief_title": "Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors", 
        "condition": "Advanced Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Voluntarily signed written informed consent\n\n          -  Age \u2265 18 years old\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of \u2264 1.\n\n          -  Life expectancy \u2265 3 months.\n\n          -  Patients with confirmed diagnosis of advanced solid tumors.\n\n          -  Patients may have received \u2264 2 chemotherapy-containing lines in the advanced setting.\n\n          -  Adequate bone marrow, renal, hepatic, and metabolic function (assessed \u2264 seven days\n             before inclusion in the study)\n\n          -  Recovery or stabilization to grade \u2264 1 from any adverse event derived from previous\n             treatment (up to grade 2 alopecia or asthenia/fatigue are allowed).\n\n          -  No clinically significant changes in ECG.\n\n          -  At least four weeks since the last monoclonal antibody containing therapy or\n             definitive radiotherapy (RT)\n\n          -  At least two weeks since the last biological/investigational single-agent therapy\n             (excluding MAbs) and/or palliative RT (\u226410 fractions or \u226430 Gy total dose)\n\n          -  Fertil women must have pregnancy excluded by appropriate testing before study entry\n\n        Exclusion Criteria:\n\n          -  Prior treatment with PM01183 or trabectedin.\n\n          -  Concomitant diseases/conditions:\n\n               -  History within the last year or presence of unstable angina, myocardial\n                  infarction, congestive heart failure, or clinically relevant valvular heart\n                  disease or symptomatic arrhythmia or any asymptomatic ventricular arrhythmia\n                  requiring ongoing treatment.\n\n               -  Ongoing, non-neoplastic, chronically active liver disease of any origin.\n\n               -  Active infection.\n\n               -  Patients who are requiring any ongoing oxygen support.\n\n               -  Known human immunodeficiency virus (HIV) infection.\n\n               -  Any other major illness.\n\n          -  Symptomatic or corticosteroid-requiring brain metastases or leptomeningeal disease\n             involvement. Patients with asymptomatic documented stable brain metastases not\n             requiring corticosteroids during the last three months are allowed.\n\n          -  Peripheral sensory/motor neuropathy grade >1. Hearing impairment grade >1.\n\n          -  Fertile men or women not using an effective method of contraception.\n\n          -  History of bone marrow or stem cell transplantation\n\n          -  Radiotherapye to >35% of the bone marrow."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980667", 
            "org_study_id": "PM1183-A-008-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "lurbinectedin (PM01183) / cisplatin", 
                "description": "lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.", 
                "intervention_name": "lurbinectedin (PM01183)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "lurbinectedin (PM01183) / cisplatin", 
                "description": "vials containing 1 mg/ml concentrate for solution for infusion", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cisplatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "lurbinectedin", 
            "PM01183", 
            "tumors", 
            "cancer", 
            "Pharma Mar"
        ], 
        "lastchanged_date": "November 4, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bellinzona", 
                        "country": "Switzerland"
                    }, 
                    "name": "Istituto Oncologico della Svizzera (IOSI), Ospedale San Giovanni."
                }, 
                "investigator": {
                    "last_name": "Cristiana Sessa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "The Cancer Institute. University College London Hospital"
                }, 
                "investigator": {
                    "last_name": "Martin Forster, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newcastle", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Northern Centre for Cancer Care, Freeman Hospital"
                }, 
                "investigator": {
                    "last_name": "Ruth Plummer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Advanced Solid Tumors", 
        "overall_official": {
            "affiliation": "Pharma Mar", 
            "last_name": "Pilar Lardelli, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the recommended dose (RD) of PM01183 in  combination with cisplatin every three weeks (q3wk) with or without aprepitant in patients with advanced solid tumors. The RD will be the dose level (DL) immediately below the maximum tolerated dose (MTD), that is, the highest DL explored at which less than one third of evaluable patients experience a DLT during Cycle 1.", 
            "measure": "Recommended dose (RD) of the combination PM01183 and cisplatin", 
            "safety_issue": "Yes", 
            "time_frame": "30 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980667"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To characterize the pharmacokinetics (PK) parameters Cmax (maximum concentratio), AUC (area under the curve), CL (clearance), HL (half life) y Vss (volume of distribution ) of this combination in patients receiving/not receiving aprepitant and to explore factors that may affect individual variability in main PK parameters.", 
                "measure": "Pharmacokinetics (PK) characterisation of Cmax (maximum concentratio), AUC (area under the curve), CL (clearance), HL (half life) y Vss (volume of distribution)", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "To conduct an exploratory pharmacogenomic (PGx) analysis to identify and validate putative molecular markers associated with the clinical outcome of patients treated with PM01183 and cisplatin. These molecular markers would help in the future selection of patients who might preferentially benefit from PM01183 therapy, thus contributing to improve health care through a more individualized medicine.", 
                "measure": "Pharmacogenomic (PGx) analysis", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }
        ], 
        "source": "PharmaMar", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PharmaMar", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}